Loading...
Market
Which company will be the primary competitor to Incyte's Niktimvo in the chronic GVHD market by the end of 2025?
2
Resolution / Starting Odds
Bristol-Myers Squibb • 25%
Novartis • 25%
Pfizer • 25%
Other • 25%
Publicly available market research reports and competitive analysis
Story
FDA Approves Incyte's Niktimvo for Chronic GVHD
Aug 14, 2024, 10:09 PM
The U.S. Food and Drug Administration (FDA) has approved Incyte Corporation's drug, Niktimvo™ (axatilimab-csfr), for the treatment of chronic graft-versus-host disease (GVHD). This condition is a potentially fatal complication that can occur after a stem cell transplant. The approval marks a significant advancement in the treatment options available for patients suffering from chronic GVHD. The drug, developed in collaboration with Syndax Pharmaceuticals, offers a new therapeutic option for managing this serious condition.
View original story
Similar markets
Bristol-Myers Squibb • 25%
Pfizer • 25%
Roche • 25%
Other • 25%
Pfizer • 25%
Merck • 25%
Johnson & Johnson • 25%
Other • 25%
Verzenio (abemaciclib) • 25%
Kisqali (ribociclib) • 25%
Enhertu (trastuzumab deruxtecan) • 25%
Other • 25%
Pfizer • 25%
Roche • 25%
AstraZeneca • 25%
Other • 25%
Biogen • 25%
Roche • 25%
Novartis • 25%
Other • 25%
Pfizer • 25%
Moderna • 25%
Roche • 25%
Other • 25%
Pfizer • 25%
Ionis Pharmaceuticals • 25%
Eidos Therapeutics • 25%
Other • 25%
Pfizer • 25%
Johnson & Johnson • 25%
Novartis • 25%
Other • 25%
Travere Therapeutics • 25%
Novartis • 25%
Calliditas • 25%
Other • 25%
CRISPR Therapeutics • 25%
Intellia Therapeutics • 25%
Beam Therapeutics • 25%
Other • 25%
Novartis • 25%
Gilead Sciences • 25%
Bristol Myers Squibb • 25%
Other • 25%
Roche • 25%
Novartis • 25%
Pfizer • 25%
Other • 25%